Sandra Rizzo
Family · Frederick, MDNPI 1396351664
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. Axonics, Inc. accounts for 67.4% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2024 at $6,151 and has fallen 99.3% since, to $45 in 2025. Among family clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 225 payments — averaging $43.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$7K
- Sumitomo Pharma America, Inc.$1K
- Astellas Pharma US Inc$494
- Urovant Sciences Inc$395
- Bayer$226
- Medtronic$217
- plus $786 from 16 others
What the payments were for
- Speaking & faculty fees$1251%
- Travel & lodging$3,84239%
- Food & beverage$5,56657%
- Education$2853%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 99 | $6,619 |
| Sumitomo Pharma America, Inc. | 39 | $1,081 |
| Astellas Pharma US Inc | 19 | $494 |
| Urovant Sciences Inc | 19 | $395 |
| Bayer | 8 | $226 |
| Medtronic | 8 | $217 |
| Teleflex LLC | 4 | $172 |
| AbbVie(2 entities) | 5 | $130 |
| Merck | 4 | $85 |
| Endo USA, Inc. | 4 | $84 |
| Millicent US Inc | 3 | $55 |
| Boston Scientific | 2 | $54 |
| Urogen Pharma, Inc. | 2 | $32 |
| Valencia Technologies Corporation | 1 | $28 |
| Coloplast | 1 | $24 |
| Tolmar, Inc. | 1 | $23 |
| Galderma Laboratories, L.p. | 1 | $17 |
| ABC Home Medical Supply, Inc. | 1 | $17 |
| Hollister Incorporated | 1 | $17 |
| 180 Medical, Inc. | 1 | $17 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,818 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 289 | $296,030 |
| MyrbetriqMirabegron | 217 | $218,065 |
| Estradiol | 212 | $15,245 |
| Mirabegron ErMirabegron | 13 | $12,581 |
| Solifenacin Succinate | 220 | $10,439 |
| Methenamine Hippurate | 63 | $6,701 |
| Tamsulosin Hcl | 257 | $6,690 |
| EstringEstradiol | 11 | $5,766 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 37 | $5,246 |
| Tolterodine Tartrate ErTolterodine Tartrate | 46 | $5,011 |
| Darifenacin ErDarifenacin Hydrobromide | 20 | $3,932 |
| Trospium Chloride ErTrospium Chloride | 18 | $3,828 |
| Fosfomycin Tromethamine | 22 | $3,509 |
| Trospium Chloride | 42 | $3,334 |
| Finasteride | 112 | $2,929 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $1,081 | $296,030289 claims |
| Astellas Pharma US IncMyrbetriq | $494 | $218,065217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.
Other family in Frederick
- Teri OneilFrederick$17K
- Lindsay BittoFrederick$10K
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Ariana ChaoLutherville$85K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Joy MaulikSalisbury$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.